Pharming Group (OTCMKTS:PHGUF) Reaches New 52-Week High - Here's What Happened
Pharming Group (OTCMKTS:PHGUF) reached a new 52-week high of $1.53 during trading, with a volume of 2,400 shares. The company reported a quarterly EPS of $0.01 and revenue of $97.30 million, exceeding analysts' expectations of $80.18 million. Pharming specializes in biopharmaceuticals for rare diseases, offering treatments like RUCONEST and Joenja. Despite a Hold rating from analysts, the stock's performance has drawn attention, although it was not included in a list of top stock recommendations.
Pharming Group NV (OTCMKTS:PHGUF - Get Free Report)'s share price hit a new 52-week high during trading on Thursday . The company traded as high as $1.53 and last traded at $1.53, with a volume of 2400 shares. The stock had previously closed at $1.50.
Get Pharming Group alerts:
Pharming Group Stock Performance
The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.07 and a current ratio of 2.79. The firm's 50 day moving average is $1.47 and its two-hundred day moving average is $1.22.
Pharming Group (OTCMKTS:PHGUF - Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The biotechnology company reported $0.01 EPS for the quarter. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. The firm had revenue of $97.30 million for the quarter, compared to analysts' expectations of $80.18 million.
Pharming Group Company Profile
(Get Free Report)Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Further Reading
- Five stocks we like better than Pharming Group
- How to Invest in Insurance Companies: A Guide
- Upwork's Stock Soars on Q3 Blowout and a New AI Blueprint
- How is Compound Interest Calculated?
- The Metals Market Is Heating Up—4 Stocks Poised to Shine
- Procter & Gamble NYSE: PG Pulls Back After Shaky Guidance
- Tempus AI: Volatility Equates to Opportunity in AI Leader
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Pharming Group Right Now?
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
